3758 results for «2020»
3758 results
Restriction in supra-annular transcatheter heart valve leaflet mobility during coronary access after valve-in-valve TAVI
05 Apr 2022
This Image in Interventional Cardiology highlights how patient-specific ex vivo simulations offer physicians the opportunity to observe and evaluate the potential in vivo impact of different techniques particularly for complex structural heart interventions.
MedAlliance SELUTION SLR Receives Coronary FDA IDE Approval
24 Oct 2022
MedAlliance to be acquired by Cordis
18 Oct 2022
COVID-19 vaccines: Burning questions from the community and real-world applicability
13 Jan 2021
View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.
Insights from the Corevalve US Pivotal and SURTAVI trials
05 Apr 2022
Pierre Deharo and Giuseppe Di Gioia provide their take on this analysis of the 5 years incidence, outcomes and predictors of hemodynamic SVD in patients undergoing TAVI and surgery from the Corevalve US Pivotal and SURTAVI trials.
Author
Author
Treatment of a huge femoral artery pseudoaneurysm with a suture based vascular closure device
17 Nov 2020
In this case, a few days after TAVI the heart team has to treat a femoral artery pseudoaneurysm on a 83-year woman. Learn more about their strategy!
Author
Author
Author
Angiography-based quantitative flow reserve in coronary vasospastic angina
03 Jun 2020
A 60-year-old woman with a history of cardiac arrest associated with MINOCA (myocardial infarction with no coronary artery disease) event in the territory of the left main artery, underwent coronary angiography for recurrent episodes of chest pain leading to 4 hospitalizations in the last 2 years...
Post-dilation from contralateral access site for nose cone entrapment during self-expandable transcatheter aortic valve implantation
07 Sep 2021
View this successful case with bail-out post-dilation for modifying nose cone entrapment due to stent frame infolding.
PCR London Valves 2021 – Welcome message
PARTNER 3: weighing the comparative costs and savings of TAVI versus SAVR in low-risk patients with severe aortic stenosis
07 Nov 2021
Professor David J. Cohen presented the results of the economic outcomes of the PARTNER 3 trial on Friday, 5 November, in the Late-Breaking Trial session of the Transcatheter Cardiovascular Therapeutics Congress 2021. Giuseppe Biondi-Zoccai provides his analysis of this study.
Author
PCR Seminars 2019
MedAlliance enrolls first US patient into its third FDA IDE Study: SFA SELUTION4SFA
04 May 2023
FDA approves US oriented clinical study of Bentley’s BeGraft and Cook’s Zenith® Fenestrated+ Endovascular Graft for treatment of aortic aneurysms CAUTION: Investigational device. Limited by United States law to investigational use.
28 Jun 2023
Enrollment completed in SAVE Trial with SELUTION SLR for treatment of AV fistulas in renal dialysis patients
14 Aug 2023
MedAlliance announces enrollment of first Patient in SELUTION SLR LOVE-DEB coronary study
07 Sep 2023
A short history of the Euro4C Group
16 Jan 2019
Who better to recount its history than the inaugural President of the Euro4C Group? Additionally, insights are provided by the Chairman of PCR, the former EAPCI President, and a pivotal member of the editorial team.
Recruitment complete in FEVAR study for on-label use with Bentley BeGraft as bridging stent
21 Jul 2022
ISCHEMIA-CKD EXTEND: revascularization does not improve outcomes at 5 years in patients with advanced chronic kidney disease
29 Aug 2022
Panagiotis Xaplanteris reports on the ISCHEMIA-CKD EXTEND trial results - clinical outcomes at 5 years of follow-up, which were presented during the ESC 2022 congress in Barcelona.
Author
Catalysing a more equitable workforce in medicine – Women as One - EuroPCR 2022
19 May 2022
Founded in 2019 by Marie-Claude Morice and Roxana Mehran, the mission of Women as One is to promote talent in medicine by providing unique professional opportunities to women physicians.
Author
Author
MedAlliance’s SELUTION SLR™ drug-eluting balloon (DEB) receives FDA Investigational Device Exemption (IDE) approval, making it the first limus DEB to be available to US patients
26 May 2022